Advertisement

Expert Point of View: Carlos L. Arteaga, MD


Advertisement
Get Permission

Carlos L. Arteaga, MD

Carlos L. Arteaga, MD

CARLOS L. ARTEAGA, MD, Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at The University of Texas Southwestern Medical Center, Dallas, expressed some caution about the overall applicability of the findings of the PADDY trial. Primarily, he noted, as with many large trials, the study was initiated many years ago, at a time when the portfolio of validated prognostic biomarkers and treatment was different.

“For example, one has to wonder if results would have been the same if patients with luminal B tumors had been treated with more current adjuvant therapy,” said Dr. Arteaga. “And it is common practice to treat most women with early operable breast cancer anyway, that is those with and without detectable disseminated tumor cells.”

DISCLOSURE: Dr. Arteaga reported no conflicts of interest.


Related Articles

Prognostic Value of Disseminated Tumor Cells in Early Breast Cancer

IN THE PADDY TRIAL, involving more than 10,000 women with early invasive breast cancer, the presence of disseminated tumor cells at diagnosis or primary surgery was an independent prognostic factor for overall, disease-free, and distant disease–free survival. The study findings were presented at...

Advertisement

Advertisement



;
Advertisement